IL99345A - 6- Or 7-(2-imino-imidazolidine) 1, 4-benzoxazines and pharmaceutical compositions comprising them - Google Patents

6- Or 7-(2-imino-imidazolidine) 1, 4-benzoxazines and pharmaceutical compositions comprising them

Info

Publication number
IL99345A
IL99345A IL9934591A IL9934591A IL99345A IL 99345 A IL99345 A IL 99345A IL 9934591 A IL9934591 A IL 9934591A IL 9934591 A IL9934591 A IL 9934591A IL 99345 A IL99345 A IL 99345A
Authority
IL
Israel
Prior art keywords
compound
carbons
lower alkyl
benzoxazine
dihydro
Prior art date
Application number
IL9934591A
Other languages
English (en)
Other versions
IL99345A0 (en
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IL99345A0 publication Critical patent/IL99345A0/xx
Publication of IL99345A publication Critical patent/IL99345A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Treating Waste Gases (AREA)
  • Cosmetics (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
IL9934591A 1990-09-12 1991-08-29 6- Or 7-(2-imino-imidazolidine) 1, 4-benzoxazines and pharmaceutical compositions comprising them IL99345A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/582,034 US5091528A (en) 1990-09-12 1990-09-12 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents

Publications (2)

Publication Number Publication Date
IL99345A0 IL99345A0 (en) 1992-07-15
IL99345A true IL99345A (en) 1998-08-16

Family

ID=24327570

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9934591A IL99345A (en) 1990-09-12 1991-08-29 6- Or 7-(2-imino-imidazolidine) 1, 4-benzoxazines and pharmaceutical compositions comprising them

Country Status (17)

Country Link
US (1) US5091528A (fr)
EP (1) EP0548254B1 (fr)
JP (1) JP3096475B2 (fr)
AT (1) ATE180782T1 (fr)
AU (1) AU646098B2 (fr)
CA (1) CA2091440C (fr)
DE (1) DE69131295T2 (fr)
ES (1) ES2132093T3 (fr)
FI (1) FI94864C (fr)
HU (1) HU220671B1 (fr)
IE (1) IE913202A1 (fr)
IL (1) IL99345A (fr)
NO (1) NO303577B1 (fr)
NZ (1) NZ239580A (fr)
PT (1) PT98959B (fr)
WO (1) WO1992004345A1 (fr)
ZA (1) ZA917218B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5252595A (en) * 1990-02-28 1993-10-12 Allergan, Inc. Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
US5716952A (en) * 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
US6077839A (en) 1992-03-19 2000-06-20 Allergan Sales, Inc. Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists
US5710288A (en) * 1993-04-21 1998-01-20 Allergan 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents
US5369127A (en) * 1993-04-21 1994-11-29 Allergan, Inc. 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents
US5663189A (en) * 1993-07-01 1997-09-02 The Procter & Gamble Company 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
US5580892A (en) * 1993-10-22 1996-12-03 Allergan Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents
NZ333370A (en) * 1993-12-17 2001-03-30 Procter & Gamble 6-(2-Imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
CA2179006A1 (fr) * 1993-12-17 1995-06-22 Peter Julian Maurer Composes de 6-(2-imidazolinylamino)quinoxaline utilises en tant qu'agonistes de l'adrenocepteur alpha-2
US5578607A (en) * 1993-12-17 1996-11-26 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US5576437A (en) * 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
EP0741709B1 (fr) * 1994-01-24 2001-07-25 Allergan Sales, Inc. Derives aromatiques 2-amino-imidazole utilises comme agonistes de l'adrenorecepteur alpha-2a
AU2829395A (en) * 1994-06-16 1996-01-05 Allergan, Inc. Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators
JPH10502643A (ja) * 1994-07-11 1998-03-10 アラーガン α▲下２▼アドレナリン遮断剤として有用な、立体配座の定まった二環およびアダマンタン誘導体
US6150389A (en) 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents
WO1996004270A1 (fr) 1994-08-04 1996-02-15 Synaptic Pharmaceutical Corporation Nouveaux derives de benzimidazole
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US6087361A (en) * 1995-05-12 2000-07-11 Allergan Sales, Inc. Aryl-imidazolines and aryl-imidazoles useful as α-2 adrenergic agonists without cardiovascular side effects
AU744018B2 (en) * 1995-05-12 2002-02-14 Allergan, Inc. Aryl-imidazolines and aryl-imidazoles useful as alpha-2 adrenergic agonists without cardiovascular side effects
EP0828491A1 (fr) * 1995-05-12 1998-03-18 Allergan Aryl-imidazolines et aryl-imidazoles utiles en tant qu'agents agonistes adrenergiques alpha-2 n'entrainant pas d'effets secondaires cardio-vasculaires
US5914342A (en) * 1995-06-07 1999-06-22 The Procter & Gamble Company 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
US5916900A (en) 1995-06-29 1999-06-29 The Procter & Gamble Company 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US6350780B1 (en) 1995-07-28 2002-02-26 Allergan Sales, Inc. Methods and compositions for drug delivery
US6306877B1 (en) * 1999-08-09 2001-10-23 The Procter & Gamble Co. Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
AU5433898A (en) * 1996-11-25 1998-06-22 Procter & Gamble Company, The 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists
CA2272683A1 (fr) * 1996-11-25 1998-06-04 The Procter & Gamble Company Composes 2-imidazolinylaminobenzoxazole convenant comme agonistes de l'adrenorecepteur .alpha.-2
CZ184099A3 (cs) 1996-11-25 1999-11-17 The Procter & Gamble Company Sloučenina, farmaceutický prostředek a způsob prevence nebo léčby
EP0944621B1 (fr) * 1996-11-25 2004-09-01 The Procter & Gamble Company Composes 2-imidazolinylaminoindole convenant comme agonistes de l'adrenorecepteur alpha-2
US6172095B1 (en) 1996-11-25 2001-01-09 The Procter & Gamble Company Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
ID24081A (id) * 1997-04-15 2000-07-06 Procter & Gamble Senyawa-senyawa 5-(2-imidazolinilamino) benzimidazol yang berguna sebagai agonis-agonis alfa-2-adrenoseptor
EP1037887B1 (fr) 1997-11-24 2004-07-14 The Procter & Gamble Company 5-(2-imidazolinylamino)-benzimidazole, derives et procedes de preparation et d'utilisation de ces derniers en tant qu'agonistes du recepteur alpha-adrenergique ayant une meilleure stabilite metabolique
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
CA2330611A1 (fr) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Molecules bifonctionnelles et therapies basees sur celles-ci
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
MXPA02002032A (es) 1999-08-27 2003-05-19 Ligand Pharm Inc Compuestos moduladores del receptor de androgeno y metodos.
US6667313B1 (en) 1999-08-27 2003-12-23 Ligand Pharmaceuticals Inc. 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
PE20010647A1 (es) 1999-09-14 2001-06-23 Lilly Co Eli Moduladores de receptores de retinoide x (rxr) con perfil farmacologico mejorado
US8858961B2 (en) * 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
WO2003009815A2 (fr) 2001-07-25 2003-02-06 Biomarin Pharmaceutical Inc. Compositions et procedes de modulation du transport a travers la barriere hematho-encephalique
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
CA2505836C (fr) * 2004-05-06 2013-08-27 Alcon Inc. Formulations topiques de tartrate de brimonidine exemptes de dioxyde de chlore
SI1889198T1 (sl) 2005-04-28 2015-02-27 Proteus Digital Health, Inc. Farma-informacijski sistem
BRPI0618643A2 (pt) 2005-11-09 2011-09-06 Combinatorx Inc composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
EP2063905B1 (fr) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Traitement des troubles hépatiques par l'administration de conjugués de protéine associée au récepteur (rap)
CA2696314C (fr) * 2007-08-15 2016-01-19 Allergan, Inc. Composes adrenergiques
EP2100598A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
DK2398500T3 (da) 2009-02-20 2019-05-13 2 Bbb Medicines B V Glutathion-baseret lægemiddelafgivelsessystem
SG175896A1 (en) 2009-05-06 2011-12-29 Lab Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
CA2777223C (fr) 2009-10-06 2017-10-24 Allergan, Inc. Derives de 2h-pyrrol-5-amine utilises en tant que modulateurs des recepteurs alpha-adrenergiques
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP2510928A1 (fr) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636219A (en) * 1964-03-02 1972-01-18 Du Pont Anticholinergic compositions containing certain thiazolines or imidazolines
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4515800A (en) * 1981-11-20 1985-05-07 Icilio Cavero Method of lowering intraocular pressure using phenylimino-imidazoles
US4587257A (en) * 1984-12-14 1986-05-06 Alcon Laboratories, Inc. Control of ocular bleeding using clonidine derivatives

Also Published As

Publication number Publication date
EP0548254A1 (fr) 1993-06-30
FI931095A7 (fi) 1993-04-22
WO1992004345A1 (fr) 1992-03-19
ES2132093T3 (es) 1999-08-16
EP0548254B1 (fr) 1999-06-02
HU220671B1 (hu) 2002-04-29
NO930898L (no) 1993-05-10
CA2091440A1 (fr) 1992-03-13
CA2091440C (fr) 2003-11-11
NO930898D0 (no) 1993-03-11
JPH06501004A (ja) 1994-01-27
NO303577B1 (no) 1998-08-03
NZ239580A (en) 1994-02-25
AU8643691A (en) 1992-03-30
ZA917218B (en) 1992-06-24
HUT65587A (en) 1994-07-28
ATE180782T1 (de) 1999-06-15
FI94864C (fi) 1995-11-10
US5091528A (en) 1992-02-25
HU9300695D0 (en) 1993-06-28
FI94864B (fi) 1995-07-31
PT98959A (pt) 1992-07-31
AU646098B2 (en) 1994-02-10
DE69131295T2 (de) 2000-01-27
PT98959B (pt) 1999-02-26
JP3096475B2 (ja) 2000-10-10
IE913202A1 (en) 1992-02-25
IL99345A0 (en) 1992-07-15
FI931095A0 (fi) 1993-03-11
DE69131295D1 (de) 1999-07-08

Similar Documents

Publication Publication Date Title
US5091528A (en) 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
EP0426390B1 (fr) Procédé pour l'utilisation de (2-imidazoline-2-ylamino)-quinoxalines pour réduire ou maintenir la pression intraoculaire
EP0422878B1 (fr) (Imidazoline-2-yl-2-amino)-tetrahydro-quinoxalines et méthodes d'utilisation
AU643316B2 (en) (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
EP0409435B1 (fr) Hétéroaryl pipérazine comme agents antipsychotiques
US5350747A (en) Heteroaryl piperazine antipsychotic agents
KR0179063B1 (ko) 항정신병 작용을 갖는 화합물
US5198442A (en) (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
KR100304177B1 (ko) (1,2,4)트리아졸로(4,3-a)퀴녹살린화합물,이의제조방법및이를함유하는약제학적조성물_
JPH07503015A (ja) （２−イミダゾリン−２−イルアミノ）キノキサリン誘導体の使用方法
KR101069948B1 (ko) 녹내장 및 근시 치료용 벤조 [ｇ] 퀴놀린 유도체
JP2005519117A (ja) キノリン誘導体
US6057334A (en) Benzo[g]quinoline derivatives
IE83705B1 (en) 6- OR 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as alpha adrenergic agents
IL97220A (en) (2-imidazolin-2-ylamino) tetrahydro-quinoxalines and pharmaceutical compositions comprising them
HK1004266B (en) (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees